Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): Predictors, characteristics, and clinical outcomes

Journal of the American College of Cardiology

Volumn 63, Issue 20, 2014, Pages 2141-2147

  Hylek, Elaine M ^a   Held, Claes ^b   Alexander, John H ^c   Lopes, Renato D ^c   De Caterina, Raffaele ^d   Wojdyla, Daniel M ^c   Huber, Kurt ^e   Jansky, Petr ^f   Steg, Philippe Gabriel ^g   Hanna, Michael ^h   Thomas, Laine ^c   Wallentin, Lars ^b   Granger, Christopher B ^c  

^a BOSTON MEDICAL CENTER   (United States)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHIETI   (Italy)

^e WILHELMINEN HOSPITAL   (Austria)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g BICHAT HOSPITAL   (France)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

atrial fibrillation; bleeding; factor Xa inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; APIXABAN; CLOPIDOGREL; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

AGED; ARTICLE; BLEEDING; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EXTRACRANIAL HEMORRHAGE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SOFT TISSUE HEMORRHAGE; SURVIVAL TIME; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; BLOOD TRANSFUSION; HOSPITALIZATION;

ATRIAL FIBRILLATION; BLEEDING; FACTOR XA INHIBITOR;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; WARFARIN; WORLD HEALTH;

EID: 84900992940     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.02.549     Document Type: Article

References (27)

1. D.S. Budnitz, M.C. Lovegrove, N. Shehab, and C.L. Richards Emergency hospitalizations for adverse drug events in older Americans N Engl J Med 365 2011 2002 2012
2. C.B. Granger, J.H. Alexander, and J.J. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
3. R.D. Lopes, J.H. Alexander, and S.M. Al-Khatib et al. Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
4. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients J Thromb Haemost 3 2005 692 694
5. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
6. N. Mackman The role of tissue factor and factor VIIa in hemostasis Anesth Analg 108 2009 1447 1452
7. F. Dentali, C. Marchesi, and M.G. Pierfranceschi et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists Thromb Haemost 106 2011 429 438
8. R. Sarode, K. Matevostan, R. Bhagat, C. Rutherford, C. Madden, and J.E. Beshay Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage J Neurosurg 116 2012 491 497
9. J.H. Baggs, A.E. Patanwala, E.M. Williams, and B.L. Erstad Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal Ann Pharmacother 46 2012 51 56
10. D.M. Witt, T. Delate, and D.A. Garcia et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin interruption for gastrointestinal bleeding Arch Intern Med 17 2012 1 8
11. E.M. Hylek, and D.E. Singer Risk factors for intracranial hemorrhage in outpatients taking warfarin Ann Intern Med 120 1994 897 902
12. R.J. Beyth, L.M. Quinn, and C.S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med 105 1998 91 99
13. B.F. Gage, Y. Yan, and P.E. Milligan et al. Clinical classification schemes for predicting haemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 2006 713 719
14. G.Y. Lip, L. Frison, J.L. Halperin, and D. Lane Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 57 2011 173 180
15. J.P. DiMarco, G. Flaker, and A.L. Waldo et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the AFFIRM study Am Heart J 149 2005 650 656
16. D. Poli, E. Antonucci, and M. Zanazzi et al. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics) Thromb Haemost 107 2012 1100 1106
17. M.C. Fang, A.S. Go, and Y. Chang et al. A new risk scheme to predict warfarin-associated hemorrhage J Am Coll Cardiol 58 2011 395 401
18. J. Hallas, M. Dall, and A. Andries et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study BMJ 333 2006 726
19. L. Mellemkjaer, W.J. Blot, and H.T. Sørensen et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark Br J Clin Pharmacol 53 2002 173 181
20. T.I. Shireman, J.D. Mahnken, P.A. Howard, T.F. Kresowik, Q. Hou, and E.F. Ellerbeck Development of a contemporary bleeding risk model for elderly warfarin recipients Chest 130 2006 1390 1396
21. T. Umemura, T. Kawamura, T. Sakakibara, S. Mashita, N. Hotta, and G. Sobue Microalbuminuria is independently associated with deep or infratentorial brain microbleeds in hypertensive adults Am J Hypertens 25 2012 430 436
22. F.C. Shen, C.T. Lee, and C.K. Sun et al. Prevalence of haematuria positively associated with urine albumin excretion in type 2 diabetes Diabet Med 29 2012 1178 1183
23. M. Levi, and K. Hovingh Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials Thromb Haemost 100 2008 1047 1051
24. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
25. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin for nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
26. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
27. A.S. Go, E.M. Hylek, and Y. Chang et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 290 2003 2685 2691